Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05160558 · ClinicalTrials.gov registry record · Phase 1
A Pharmacokinetics and Safety Study of BIIB132 in Adults With Spinocerebellar Ataxia 3
A Phase 1 study, sponsored by Biogen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT05160558 is a Phase 1 study that was terminated before completion, run by Biogen. The registered enrollment target is 8 participants.
The verdict
NCT05160558, a Phase 1 study, was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety and tolerability of multiple ascending doses of BIIB132 administered via intrathecal (IT) injection to participants with spinocerebellar ataxia type 3 (SCA3). The secondary objective of this study is to characterize the multiple-dose pharmacokinetics (PK) of BIIB132 administered via IT injection to participants with SCA3.
Interventions
- DRUG BIIB132
- DRUG BIIB132-Matching Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2022-02-02 |
| Est. Completion | 2023-07-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05160558
The ClinicalTrials.gov registry entry for NCT05160558 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BIIB132 is the first listed.
NCT05160558 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05160558 about?
NCT05160558 is a clinical study titled "A Pharmacokinetics and Safety Study of BIIB132 in Adults With Spinocerebellar Ataxia 3". The primary objective of this study is to evaluate the safety and tolerability of multiple ascending doses of BIIB132 administered via intrathecal (IT) injection to participants with spinocerebellar ataxia type 3 (SCA3). The secondary objective of this study is to characterize the multiple-dose phar...
What is the current status of trial NCT05160558?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2022-02-02. Estimated completion is 2023-07-25.
What interventions are being tested in trial NCT05160558?
The interventions under investigation include: BIIB132 (DRUG), BIIB132-Matching Placebo (DRUG).
Who is sponsoring clinical trial NCT05160558?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.